Is Amgen (AMGN) a risky stock?
As of July 21, 2026, Clavix grades Amgen (AMGN) C+ for risk, a composite score of 61 out of 100 on an A+ to F scale, which puts AMGN in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind AMGN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how AMGN scores on each, as of July 21, 2026.
What's moving AMGN's risk right now
Company-specific signals Clavix flags behind AMGN's current grade, drawn from recent news and filings as of July 21, 2026.
Accord BioPharma now sells two pegfilgrastim biosimilars (ENNUMO and UDENYCA) plus a filgrastim biosimilar, adding pricing and share pressure on Amgen's NEULASTA franchise.
Bartlett & CO. cut its AMGN stake by 5.2% while SteelPeak Wealth added shares, and Amgen filed a routine 8-K material event report on July 17. No clear signal from the activity.
Wall Street expects Amgen to top estimates again next quarter, though the article notes upside may already be in the price. Thirty covering brokerages rate the stock a Hold overall.
What a C+ grade means
On the Clavix A+ to F scale, AMGN's composite of 61 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell AMGN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.